Aurealis Therapeutics AG
Multi-target cell and gene therapy platform
Discover the mode of action of our lead clinical asset AUP-16, a topical cell therapy that enables the healing of Diabetic Foot Ulcers (DFU) and other chronic, non-healing wounds.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
09.12.2025
Promising progress for therapies against critical medical needs (startupticker.ch)
15.11.2024
Aurealis Therapeutics raises CHF8 million (startupticker.ch)
06.11.2024
Biotech companies report progress in clinical trials (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Aurealis Therapeutics AG
Multi-target cell and gene therapy platform
Website:
aurealistherapeutics.com/
Headquarter:
Basel
Foundation Date:
December 2018
Technology:
- Medtech